Cargando…

Devalued and Distrusted : Can the Pharmaceutical Industry Restore Its Broken Image? /

"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former P...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: LaMattina, John L.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Hoboken, New Jersey : Wiley, [2013]
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 EBOOKCENTRAL_ocn831464032
003 OCoLC
005 20240329122006.0
006 m o d
007 cr |n|||||||||
008 121010s2013 nju ob 001 0 eng d
010 |z  2012032915 
040 |a AZU  |b eng  |e pn  |c AZU  |d OCLCO  |d CCO  |d IDEBK  |d E7B  |d GPM  |d OCLCF  |d YDXCP  |d RECBK  |d MHW  |d EBLCP  |d N$T  |d DG1  |d TEFOD  |d DEBSZ  |d UKDOC  |d LRU  |d GGVRL  |d OCLCQ  |d AU@  |d CDX  |d DEBBG  |d TEFOD  |d OCLCQ  |d COO  |d OCLCQ  |d NKT  |d AZK  |d COCUF  |d DG1  |d MOR  |d LIP  |d PIFAG  |d MERUC  |d OCLCQ  |d ZCU  |d U3W  |d OCLCQ  |d STF  |d HCO  |d WRM  |d NRAMU  |d OCLCA  |d ICG  |d INT  |d VT2  |d OCLCQ  |d WYU  |d UWO  |d OCLCQ  |d DKC  |d OCLCO  |d OCLCQ  |d UKAHL  |d OCLCQ  |d OCLCA  |d UKCRE  |d BOL  |d OCLCA  |d OCLCO  |d OCL  |d OCLCQ  |d INARC  |d OCLCO  |d OCLCL 
019 |a 823389919  |a 829353805  |a 864914474  |a 880910023  |a 961488066  |a 962624123  |a 988468055  |a 991990834  |a 992868798  |a 1037786649  |a 1038681796  |a 1045491112  |a 1055334368  |a 1065714583  |a 1067252213  |a 1081261100  |a 1114392020  |a 1153513096  |a 1228600576  |a 1244448506  |a 1249217519  |a 1391393876 
020 |a 9781118487471  |q (pbk.) 
020 |a 1118487478  |q (pbk.) 
020 |a 9781283917421  |q (MyiLibrary) 
020 |a 1283917424  |q (MyiLibrary) 
020 |a 9781118511251  |q (electronic bk.) 
020 |a 1118511255  |q (electronic bk.) 
020 |a 9781118511299  |q (electronic bk.) 
020 |a 1118511298  |q (electronic bk.) 
020 |a 9781118511329  |q (electronic bk.) 
020 |a 1118511328  |q (electronic bk.) 
028 0 1 |a EB00063788  |b Recorded Books 
029 1 |a AU@  |b 000050591439 
029 1 |a AU@  |b 000051955577 
029 1 |a AU@  |b 000052918221 
029 1 |a AU@  |b 000054754255 
029 1 |a CHNEW  |b 000941567 
029 1 |a CHVBK  |b 480218439 
029 1 |a DEBBG  |b BV040884467 
029 1 |a DEBBG  |b BV041052577 
029 1 |a DEBBG  |b BV041906704 
029 1 |a DEBBG  |b BV043395679 
029 1 |a DEBBG  |b BV044171741 
029 1 |a DEBSZ  |b 397453892 
029 1 |a DEBSZ  |b 485035138 
029 1 |a GBVCP  |b 73907802X 
029 1 |a NZ1  |b 14976927 
035 |a (OCoLC)831464032  |z (OCoLC)823389919  |z (OCoLC)829353805  |z (OCoLC)864914474  |z (OCoLC)880910023  |z (OCoLC)961488066  |z (OCoLC)962624123  |z (OCoLC)988468055  |z (OCoLC)991990834  |z (OCoLC)992868798  |z (OCoLC)1037786649  |z (OCoLC)1038681796  |z (OCoLC)1045491112  |z (OCoLC)1055334368  |z (OCoLC)1065714583  |z (OCoLC)1067252213  |z (OCoLC)1081261100  |z (OCoLC)1114392020  |z (OCoLC)1153513096  |z (OCoLC)1228600576  |z (OCoLC)1244448506  |z (OCoLC)1249217519  |z (OCoLC)1391393876 
037 |a 684D5251-34C3-4198-A03A-18F445996D72  |b OverDrive, Inc.  |n http://www.overdrive.com 
050 4 |a HD9665.5  |b .L36 2013eb 
072 7 |a BUS  |x 070130  |2 bisacsh 
082 0 4 |a 338.4/76151  |2 23 
084 |a MED071000  |2 bisacsh 
049 |a UAMI 
100 1 |a LaMattina, John L. 
245 1 0 |a Devalued and Distrusted :  |b Can the Pharmaceutical Industry Restore Its Broken Image? /  |c John L. LaMattina, PhD. 
260 |a Hoboken, New Jersey :  |b Wiley,  |c [2013] 
300 |a 1 online resource (ix, 125 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
340 |g polychrome.  |2 rdacc  |0 http://rdaregistry.info/termList/RDAColourContent/1003 
347 |a data file 
500 |a Includes index. 
500 |a Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts. 
588 0 |a Print version record. 
520 |a "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--  |c Provided by publisher 
504 |a Includes bibliographical references and index. 
505 0 |a 1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Pharmaceutical industry  |x Corrupt practices. 
650 0 |a Pharmaceutical industry. 
650 1 2 |a Drug Industry  |x organization & administration 
650 2 2 |a Consumer Product Safety 
650 2 2 |a Fraud  |x prevention & control 
650 2 2 |a Pharmaceutical Preparations  |x standards 
650 2 2 |a Public Policy 
650 2 2 |a Drug Industry 
650 2 2 |a Economics, Pharmaceutical 
650 6 |a Industrie pharmaceutique  |x Pratiques déloyales. 
650 6 |a Industrie pharmaceutique. 
650 6 |a Pharmacoéconomie. 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a Pharmaceutical industry  |2 fast 
650 7 |a Pharmaceutical industry  |x Corrupt practices  |2 fast 
758 |i has work:  |a Devalued and Distrusted (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCFGbR4MHBHffPkYYcG7KtX  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |a LaMattina, John L.  |t Devalued and distrusted.  |d Hoboken, New Jersey : John Wiley & Sons, Inc., [2013]  |z 9781118487471  |w (DLC) 2012032915  |w (OCoLC)811597120 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=1104475  |z Texto completo 
936 |a BATCHLOAD 
938 |a 123Library  |b 123L  |n 62749 
938 |a Askews and Holts Library Services  |b ASKH  |n AH24924863 
938 |a Coutts Information Services  |b COUT  |n 24480295 
938 |a EBL - Ebook Library  |b EBLB  |n EBL1104475 
938 |a ebrary  |b EBRY  |n ebr10641813 
938 |a EBSCOhost  |b EBSC  |n 517869 
938 |a Cengage Learning  |b GVRL  |n GVRL8FPJ 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n cis24480295 
938 |a Recorded Books, LLC  |b RECE  |n rbeEB00063788 
938 |a YBP Library Services  |b YANK  |n 9661994 
938 |a YBP Library Services  |b YANK  |n 9961453 
938 |a YBP Library Services  |b YANK  |n 12672780 
938 |a Internet Archive  |b INAR  |n devalueddistrust0000lama 
994 |a 92  |b IZTAP